Inhibition of the B cell by CD22: A requirement for Lyn

被引：163

作者：

Smith, KGC

Tarlinton, DM

Doody, GM

Hibbs, ML

Fearon, DT ^{[1
]}

机构：

[1] Univ Cambridge, Sch Clin Med, Dept Med, Wellcome Trust Immunol Unit, Cambridge CB2 2SP, England

[2] Royal Melbourne Hosp, Walter & Eliza Hall Inst Med Res, Parkville, Vic 3050, Australia

[3] Royal Melbourne Hosp, Ludwig Inst Canc Res, Tumor Biol Branch, Parkville, Vic 3050, Australia

来源：

JOURNAL OF EXPERIMENTAL MEDICINE | 1998年 / 187卷 / 05期

基金：

英国惠康基金;

关键词：

D O I：

10.1084/jem.187.5.807

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Mice in which the Lyn, Cd22, or Shp-1 gene has been disrupted have hyperactive B cells and autoantibodies. We find that in the absence of Lyn, the ability of CD22 to become tyrosine phosphorylated after Ligation of mIg, to recruit SHP-1, and to suppress mig-induced elevation of intracellular [Ca2+] is lost. Therefore, Lyn is required for the SHP-1-mediated B cell suppressive function of CD22, accounting for similarities in the phenotypes of these mice.

引用

页码：807 / 811

页数：5

共 50 条

[21] Glycan probes of CD22 function in B cell signalling and endocytosis
Collins, BE
Han, S
Smith, BA
Bengston, P
Tateno, H
Bovin, N
Blixt, O
Paulson, JC
IMMUNOLOGY, 2005, 116 : 65 - 65
[22] Expression and function of CD22, a B-cell restricted molecule
Moyron-Quiroz, JE
Partida-Sánchez, S
Donís-Hernández, R
Sandoval-Montes, C
Santos-Argumedo, L
SCANDINAVIAN JOURNAL OF IMMUNOLOGY, 2002, 55 (04) : 343 - 351
[23] CD22 is a negative regulator of B-cell receptor signalling
Nitschke, L
Carsetti, R
Ocker, B
Kohler, G
Lamers, MC
CURRENT BIOLOGY, 1997, 7 (02) : 133 - 143
[24] Epratuzumab: Targeting B-cell malignancies through CD22
Coleman, M
Goldenberg, DM
Siegel, AB
Ketas, JC
Ashe, M
Fiore, JM
Leonard, JP
CLINICAL CANCER RESEARCH, 2003, 9 (10) : 3991S - 3994S
[25] CD22: A Regulator of Innate and Adaptive B Cell Responses and Autoimmunity
Clark, Edward A.
Giltiay, Natalia V.
FRONTIERS IN IMMUNOLOGY, 2018, 9
[26] REGULATION OF CD45 ENGAGEMENT BY THE B-CELL RECEPTOR CD22
SGROI, D
KORETZKY, GA
STAMENKOVIC, I
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1995, 92 (09) : 4026 - 4030
[27] Regulation of Human CD27+IgM+B Cell Activation by Cis-Binding of the Inhibitory Molecule CD22 to CD22 Ligand (CD22L)
Dijke, Esme
Derkatz, Kim
Pearcey, Jean
Wong, Fred
Motyka, Bruce
West, Lori
TRANSPLANTATION, 2017, 101 (05) : S5 - S5
[28] Masking of CD22 by cis ligands does not prevent redistribution of CD22 to sites of cell contact
Collins, BE
Blixt, O
DeSieno, AR
Bovin, N
Marth, JD
Paulson, JC
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2004, 101 (16) : 6104 - 6109
[29] CD22/Lyn-mediated suppression of trophoblast antigen-specific B cells underlies fetomaternal tolerance
Rizzuto, Gabrielle
Brooks, Jeremy
Fisher, Susan
Zikherman, Julie
Erlebacher, Adrian
JOURNAL OF IMMUNOLOGY, 2021, 206
[30] Analysis of tyrosine phosphorylation sites of CD22 upon B cell activation
Fujimoto, M
Yoshitake, S
Tedder, TF
Takehara, K
FASEB JOURNAL, 2005, 19 (04): : A953 - A953

← 1 2 3 4 5 →